When the Embryo Is Normal but Implantation Fails: Understanding Recurrent Implantation Failure

For patients who have transferred multiple high-quality, chromosomally tested embryos without achieving a sustained pregnancy, the emotional and cognitive weight can be profound. You have done the science. You have undergone preimplantation genetic testing. The reports confirm euploid embryos. And still, the transfers have not worked.

This experience has a clinical name—recurrent implantation failure, or RIF—and it sits at one of the more contested frontiers in reproductive medicine. The frustration is compounded by a hard truth: despite decades of research, the field does not yet have a unified definition of RIF, a single reliable diagnostic protocol, or a universally effective treatment pathway. What it does have is a growing body of evidence pointing toward several contributing mechanisms, along with an honest acknowledgment that much remains unknown.

Defining the Problem

There is no single consensus definition of recurrent implantation failure in the United States or internationally. Some clinicians apply the term after two failed transfers of chromosomally normal embryos; others require three or more. The lack of standardization is not merely semantic—it affects which patients receive additional workup, which interventions are offered, and how outcomes are compared across studies.

What most definitions share is the implicit requirement that the embryos themselves are not the primary variable. When transfers involve untested embryos, the most statistically common reason for failure is chromosomal abnormality in the embryo. Once PGT-A testing removes that variable from the equation, the clinical picture shifts toward the uterine environment and the interaction between embryo and endometrium.

The Endometrium: Receptivity Is Not Binary

The uterine lining does not simply wait, passively, for an embryo to arrive. Endometrial receptivity is an active, time-sensitive biological state governed by a cascade of hormonal signals, cell surface proteins, and molecular interactions. During a natural cycle, there is a narrow window—typically estimated at roughly four to five days—during which the endometrium is maximally receptive to implantation. This is referred to as the window of implantation, or WOI.

In frozen embryo transfer cycles, the timing of the WOI is estimated based on progesterone exposure. The standard protocol—typically five days of progesterone prior to transfer—works well for most patients. However, research has suggested that a subset of women have a displaced WOI, meaning their peak receptivity occurs earlier or later than the protocol assumes.

The Endometrial Receptivity Analysis (ERA) test, developed in Spain and now available at numerous US fertility centers, uses gene expression profiling of an endometrial biopsy to assess whether a patient's WOI aligns with the standard protocol. ERA has generated considerable debate. Proponents cite studies showing improved outcomes in patients with displaced WOI who undergo personalized transfer timing. Critics note that large randomized controlled trials have not confirmed universal benefit, and that the test adds cost and an additional biopsy cycle. The current clinical consensus, reflected in guidance from the American Society for Reproductive Medicine (ASRM), is that ERA may be appropriate in select RIF cases but should not be routinely recommended for all patients.

Immune Factors: Promising, Contested, and Complicated

The immune environment of the uterus at the time of implantation is an area of active and genuinely unresolved research. Implantation requires a carefully orchestrated immune tolerance—the maternal immune system must recognize the embryo as a tolerable foreign entity rather than a threat to be eliminated.

Natural killer (NK) cells in the uterine lining play a central role in this process. Uterine NK cells differ from peripheral NK cells in both phenotype and function, and they appear to support trophoblast invasion and early placentation. Some researchers have proposed that elevated or dysregulated uterine NK cell activity may contribute to implantation failure, and testing for NK cell levels—both peripheral and endometrial—has been offered at some fertility practices.

However, the evidence base for treating elevated NK cells in RIF patients remains limited and contested. Interventions such as intravenous immunoglobulin (IVIG), intralipid infusions, and corticosteroid protocols have been used by some clinicians, but none has been validated in large, well-controlled trials. The ASRM and other professional bodies have urged caution, noting that unproven immune interventions carry real risks and financial costs without established benefit for the general RIF population.

Other immune-related hypotheses—including autoimmune thyroid dysfunction, antiphospholipid antibody syndrome, and HLA compatibility between partners—have received varying degrees of research attention. Antiphospholipid syndrome, a condition involving abnormal blood clotting, is one of the better-characterized immune contributors to pregnancy loss and implantation failure, and testing for it is more broadly endorsed.

Structural Considerations

Before attributing implantation failure to molecular or immunological factors, structural evaluation of the uterine cavity is essential. Submucosal fibroids, endometrial polyps, intrauterine adhesions (Asherman's syndrome), and a septate uterus can all mechanically impair implantation.

Saline infusion sonography (SIS), hysteroscopy, and three-dimensional ultrasound each offer different diagnostic windows into uterine anatomy. Hysteroscopy—a direct visualization of the uterine cavity—is considered the gold standard and is often recommended prior to or during an RIF workup. Correcting identifiable structural abnormalities before proceeding with additional transfers is one of the more straightforward and evidence-supported steps in RIF management.

Chronic endometritis, a low-grade inflammation of the uterine lining often caused by bacterial infection, has also received increasing attention as a potential contributor to RIF. It is typically diagnosed via endometrial biopsy and treated with targeted antibiotics. While the evidence connecting chronic endometritis to RIF is not conclusive, it is more robust than for many other proposed mechanisms, and testing for it has become a relatively common component of RIF workups at US fertility centers.

The Honest Conversation About Unexplained RIF

After a thorough workup—structural assessment, endometrial evaluation, and relevant immune testing—a meaningful proportion of RIF patients will have no identifiable cause. This is genuinely difficult to communicate and to receive. The absence of a diagnosis does not mean the absence of a problem; it reflects the current limits of diagnostic technology and scientific understanding.

For these patients, empirical interventions—treatments applied without a confirmed diagnosis—are sometimes offered. These may include modified stimulation protocols, different endometrial preparation regimens, or adjuvant medications. The evidence supporting most empirical interventions in unexplained RIF is limited, and honest clinicians will frame them as reasonable attempts rather than proven solutions.

It is also worth acknowledging that some patients with unexplained RIF will succeed on a subsequent transfer without any protocol change. The biology of implantation involves stochastic elements—chance factors—that even the best-designed clinical protocols cannot fully control.

Moving Forward With Realistic Expectations

Navigating recurrent implantation failure requires a particular kind of resilience: the willingness to continue pursuing answers while accepting that some questions may not have answers available yet. Working with a reproductive endocrinologist who is willing to engage in an evidence-based, individualized workup—and to be transparent about what the evidence does and does not support—is the most important foundation for that process.

Asking your care team which specific evaluations they recommend and why, what the evidence base is for any proposed intervention, and what the realistic probability of success looks like with additional transfers are all appropriate and important questions. You deserve a thoughtful, honest response to each of them.